COZADD BRUCE C sold $1.3M of JAZZ
COZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $215.84 ($1.30M total) on 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the director's ownership, which may be interpreted as a lack of confidence, potentially prompting short‑term price pressure.
Market read
Insider sales are closely watched; this filing provides fresh data that could influence short‑term trading decisions.
What to watch
The 10b5-1 plan indicates the sale was pre‑scheduled, reducing the informational weight of the transaction.
Background
Form 4 filings disclose insider transactions; directors often use 10b5-1 plans to sell shares systematically.
Ticker impact
Director Cozadd Bruce C sold 6,000 shares for $1.295M via a 10b5-1 plan, reducing his stake to 339,875 shares.
likely pressure as the market prices in the insider sell
Form 4 is a primary source; a $1.3M sale by a director is material and new, suggesting potential negative sentiment.
Market effects
Minimal impact on the broader biotech/pharma sector; isolated insider transaction.
Limited to U.S. markets where Jazz trades.
Low global relevance beyond investors tracking insider activity.
Counterpoint
The sale could be routine portfolio rebalancing under a pre‑arranged plan, not a bearish signal.
Key entities
- CompanyJazz Pharmaceuticals plc
U.S.-listed biopharma company (NASDAQ:JAZZ) subject of the insider sale.
- PersonCozadd Bruce C
Director of Jazz Pharmaceuticals who executed the sale.
